期刊
HUMAN GENE THERAPY
卷 17, 期 1, 页码 117-124出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2006.17.117
关键词
-
资金
- NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014567] Funding Source: NIH RePORTER
- NCI NIH HHS [CA103579-01] Funding Source: Medline
- NCRR NIH HHS [C06RR14567] Funding Source: Medline
The potential of short interfering RNA ( siRNA) to be developed for therapeutic use against cancer depends on the availability of an efficient tumor-specific delivery vehicle. We have previously shown that a nanoscale nonviral liposome-based complex that includes an anti-transferrin receptor single-chain antibody fragment as the targeting moiety can, when systemically administered, specifically and efficiently target primary and metastatic tumors and deliver molecules useful in gene medicine, including plasmid DNA and antisense oligonucleotides. Here we explore the ability of this complex to deliver a fluorescein-labeled siRNA to tumor cells in vivo and examine the intracellular localization in vitro by confocal microscopy. We show that the immunoliposome-siRNA complex maintains its nanoscale size and, using three separate tumor models, can efficiently and specifically deliver siRNA to both primary and metastatic disease after systemic delivery, thus increasing the possibility for translating the potent effects of siRNA observed in vitro into clinically useful therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据